Novo Nordisk Pulls Unlucky NovoSeven Application In EU
This article was originally published in The Pink Sheet Daily
Executive Summary
Novo Nordisk will resubmit the application for its factor VIIa product for a supplemental intracerebral hemorrhage indication.
You may also be interested in...
Novo Drops NovoSeven Stroke Program Following Phase III Failure
Danish firm says studies of the coagulation factor in cardiac surgery and trauma will move ahead as planned.
Novo Drops NovoSeven Stroke Program Following Phase III Failure
Danish firm says studies of the coagulation factor in cardiac surgery and trauma will move ahead as planned.
NovoSeven Wins Expanded Indication For Acquired Hemophilia
Novo Nordisk’s coagulation Factor VIIa is the first recombinant therapy approved for treatment of acquired hemophilia.